As our nation ages, with the need to address more mental health and loneliness challenges than ever, it is time to design new ...

On September 30, a federal district judge in Florida held for the first time that lawsuits initiated by whistleblowers under the False Claims Act are unconstitutional, dismissing a Medicare fraud case ...

Health Affairs' Editor-in-Chief Alan Weil interviews Janice Jhang of Harvard University about her recent paper that explores how regulatory and market forces are driving adoption of biosimilars.

The policies proposed by Project 2025, if implemented, could fundamentally reshape not only the landscape of reproductive ...

Before the COVID-19 pandemic, for-profit nursing homes’ revenue generally covered their costs, whereas not-for-profit nursing homes often needed donations and other nonpatient revenue to cover ...

Biosimilars present a key opportunity to contain the growing cost of biologic drug spending and to make essential medications more affordable. However, the lackluster performance of the US biosimilar ...

Regulation of health system consolidation should take into account all aspects of the market for health care goods and ...

Instead of abolishing health savings accounts, we could turn them into vehicles for patients to get more cost-effective, ...

The NIH’s current system for funding scientific research perpetuates health disparities by privileging established, well-resourced institutions and reinforcing an individual-level focus on disease ...

Using the analogy of chess, we suggest tobacco control in the US has reached an endgame phase, during which public health ...

The sweeping relief sought by plaintiffs could erode protections for consumers against unanticipated financial liabilities ...

In anticipation of the end of the COVID-19 public health emergency, Congress ended the Medicaid continuous coverage ...